BioTelemetry (NASDAQ:BEAT) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, November 9th, BidAskClub reports.
A number of other brokerages have also recently weighed in on BEAT. Raymond James cut BioTelemetry from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Zacks Investment Research lowered BioTelemetry from a “buy” rating to a “hold” rating in a research report on Friday, August 2nd. TheStreet downgraded BioTelemetry from a “b-” rating to a “c+” rating in a report on Friday, August 16th. ValuEngine raised BioTelemetry from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Finally, Lake Street Capital restated a “buy” rating and issued a $80.00 price target (down previously from $90.00) on shares of BioTelemetry in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $71.83.
NASDAQ BEAT traded down $0.09 on Friday, reaching $46.65. The company had a trading volume of 286,151 shares, compared to its average volume of 447,299. BioTelemetry has a 52-week low of $37.07 and a 52-week high of $80.92. The stock has a market capitalization of $1.58 billion, a P/E ratio of 24.05, a P/E/G ratio of 2.37 and a beta of 1.32. The company’s fifty day moving average is $43.09 and its 200 day moving average is $44.16. The company has a quick ratio of 2.35, a current ratio of 2.46 and a debt-to-equity ratio of 0.51.
BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.02. The company had revenue of $111.30 million during the quarter, compared to the consensus estimate of $111.19 million. BioTelemetry had a return on equity of 21.77% and a net margin of 8.98%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.53 EPS. On average, research analysts expect that BioTelemetry will post 1.96 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI bought a new position in shares of BioTelemetry in the second quarter worth about $29,000. NumerixS Investment Technologies Inc purchased a new stake in shares of BioTelemetry in the second quarter worth approximately $29,000. Capital Investment Advisory Services LLC purchased a new stake in shares of BioTelemetry in the second quarter worth approximately $45,000. Tower Research Capital LLC TRC purchased a new stake in shares of BioTelemetry in the second quarter worth approximately $50,000. Finally, Quantamental Technologies LLC purchased a new stake in shares of BioTelemetry in the second quarter worth approximately $52,000. 94.19% of the stock is owned by hedge funds and other institutional investors.
BioTelemetry Company Profile
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Featured Story: Why is the ex-dividend date different from the record date?
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.